Fentanyl

Generic Name: Fentanyl

Brand Names: Abstral, Actiq, Duragesic, Effentora, Fentora, Instanyl, Lazanda, Sublimaze, Subsys, PecFent

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₈N_₂O

CAS Number: 437-38-7

Unique Ingredient Identifier: UF599785JZ

Background: Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia. Fentanyl is related to other opioids like morphine and oxycodone.

Fentanyl's high potency has also made it a common adulterant in illicit drugs, especially heroin. In 2017, 47600 overdose deaths in the United States involved some opioid (over 2/3 of all overdose deaths). Opioid overdoses kill an average of 11 Canadians daily.

Fentanyl was FDA approved in 1968.

Indication: Fentanyl intravenous or intramuscular injections are indicated for short term analgesia during induction, maintenance, and recovery from general or regional anesthesia. These injections are also used with a neuroleptic for premedication, induction, and as an adjunct to maintenance of anesthesia. Finally, fentanyl intravenous or intramuscular injections are used with oxygen for anesthesia in high risk patients.

Fentanyl sublingual tablets, transmucosal lozenges, buccal tablets, sublingual sprays, transdermal systems, and nasal sprays are indicated for the management of breakthrough pain in opioid tolerant cancer patients who require around the clock pain management.

Associated Conditions: Cancer Related Pain (Breakthrough Pain), Severe, Chronic Pain

Associated Therapies: Anesthetic premedication therapy, Anesthetics Agent, General Anesthesia, Induction of anesthesia therapy, Maintenance of anesthesia therapy, Regional Anesthesia therapy

Clinical Trials

Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Chronic, Moderate to Severe Non-Malignant Pain

Phase 3

Terminated

Conditions: Pain

Interventions: Drug: Fentanyl Transdermal Matrix Patch ZR-02-01

First Posted Date: 2005-08-04

Last Posted Date: 2012-06-05

Lead Sponsor: ZARS Pharma Inc.

Target Recruit Count: 105

Registration Number: NCT00126763

Locations: 🇺🇸
Drug Studies America, Marietta, Georgia, United States
🇺🇸
Pain Management Institute, Overland Park, Kansas, United States
🇺🇸
Loma Linda Center for Pain Management, Loma Linda, California, United States

and more 3 locations

Sensory Examination and Pharmacological Modulation of Oral Hyperexcitability in Patients With Atypical Odontalgia and Matched Healthy Controls

Phase 4

Completed

Conditions: Odontalgia

First Posted Date: 2005-06-21

Last Posted Date: 2006-06-20

Lead Sponsor: University of Aarhus

Target Recruit Count: 20

Registration Number: NCT00115102

Locations: 🇩🇰
Danish Pain Research Center, Aarhus, Denmark

Characterization of Pain Processing Mechanisms in Irritable Bowel Syndrome

Phase 2

Completed

Conditions: Irritable Bowel Syndrome

First Posted Date: 2005-04-18

Last Posted Date: 2009-01-21

Lead Sponsor: US Department of Veterans Affairs

Registration Number: NCT00108446

Locations: 🇺🇸
Malcom Randall VAMC, Gainesville, Florida, United States

OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients

Phase 3

Completed

Conditions: Pain
Cancer

First Posted Date: 2005-03-21

Last Posted Date: 2012-06-29

Lead Sponsor: Cephalon

Target Recruit Count: 300

Registration Number: NCT00105937

Locations: 🇺🇸
Cancer Care Centers of South Texas, San Antonio, Texas, United States
🇺🇸
Hunstman Cancer Institute, Salt Lake City, Utah, United States
🇺🇸
Palliative Care and Pain Medicine, Salt Lake City, Utah, United States

and more 40 locations

Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients

Phase 3

Completed

Conditions: Pain
Cancer

First Posted Date: 2005-03-14

Last Posted Date: 2014-05-09

Lead Sponsor: Cephalon

Target Recruit Count: 100

Registration Number: NCT00105287

Locations: 🇺🇸
Advanced Clinical Research Institute, Anaheim, California, United States
🇺🇸
Lehigh Valley Hospital, Allentown, Pennsylvania, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 23 locations